HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides

Human Immunology

Volumn 74, Issue 10, 2013, Pages 1280-1287

  Pezeshki, Abdul Mohammad ^a   Azar, Georges A ^a,e   Mourad, Walid ^b   Routy, Jean Pierre ^c   Boulassel, Mohamed Rachid ^c   Denzin, Lisa K ^d   Thibodeau, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

^e INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CLASS II ASSOCIATED INVARIANT CHAIN PEPTIDE; HLA DM ANTIGEN; HLA DO ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; SMALL INTERFERING RNA; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; DISSOCIATION; GENE SILENCING; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPLEEN CELL;

ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; BACTERIAL TOXINS; CELL LINE; ENTEROTOXINS; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HUMANS; MICE; PROTEIN BINDING; SUPERANTIGENS;

EID: 84883825805     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.05.010     Document Type: Article

References (80)

1. Dellabona P., Peccoud J., Kappler J., Marrack P., Benoist C., Mathis D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell 1990, 62:1115-1121.
2. Proft T., Fraser J.D. Bacterial superantigens. Clin Exp Immunol 2003, 133:299-306.
3. Kawabe Y., Ochi A. Selective anergy of Vb8+, CD4+ T cells in Staphylococcus enterotoxin B-primed mice. J Exp Med 1990, 172:1065-1070.
4. Marrack P., Blackman M., Kushnir E., Kappler J. The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med 1990, 171:455-464.
5. Acha-Orbea H., MacDonald H.R. Superantigens of mouse mammary tumor virus. Annu Rev Immunol 1995, 13:459-486.
6. McCormick J.K., Yarwood J.M., Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001, 55:77-104.
7. Baker M.D., Acharya K.R. Superantigens: structure-function relationships. Int J Med Microbiol 2004, 293:529-537.
8. Sundberg E.J., Deng L., Mariuzza R.A. TCR recognition of peptide/MHC class II complexes and superantigens. Semin Immunol 2007, 19:262-271.
9. Kim J., Urban R.G., Strominger J.L., Wiley D.C. Crystallographic structure of toxic shock syndrome toxin-1 complexed with a human class II major histocompatibility molecule HLA-DR1. Science 1994, 266:1870-1874.
10. Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G., Chi Y.I., et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368:711-718.
11. Baker M., Gutman D.M., Papageorgiou A.C., Collins C.M., Acharya K.R. Structural features of a zinc binding site in the superantigen strepococcal pyrogenic exotoxin A (SpeA1): implications for MHC class II recognition. Protein Sci 2001, 10:1268-1273.
12. Seth A., Stern L.J., Ottenhoff T.H.M., Engel I., Owen M.J., Lamb J.R., et al. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature 1994, 369:324-327.
13. Hudson K.R., Tiedemann R.E., Urban R.G., Lowe S.C., Strominger J.L., Fraser J.D. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J Exp Med 1995, 182:711-720.
14. Mehindate K., Thibodeau J., Dohlsten M., Kalland T., Sekaly R.-P., Mourad W., et al. Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med 1995, 182:1573-1577.
15. Schneider R., Lees R.K., Pedrazzini T., Zinkernagel R.M., Hengartner H., MacDonald H.R. Postnatal disappearance of self-reactive (Vb6+) cells from the thymus of Mlsa mice. Implications for T cell development and autoimmunity. J Exp Med 1989, 169:2149-2158.
16. Thibodeau J., Cloutier I., Lavoie P.M., Labrecque N., Mourad W., Jardetzky T., et al. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science 1994, 266:1874-1878.
17. Woodland D.L., Wen R., Blackman M.A. Why do superantigens care about peptides?. Immunol Today 1997, 18:18-22.
18. Kozono H., Parker D., White J., Marrack P., Kappler J. Multiple binding sites for bacterial superantigens on soluble class II major histocompatibility complex molecules. Immunity 1995, 3:187-196.
19. Von Bonin A., Ehrlich S., Malcherek G., Fleischer B. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1. Eur J Immunol 1995, 25:2894-2898.
20. Hogan R.J., VanBeek J., Broussard D.R., Surman S.L., Woodland D.L. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells. J Immunol 2001, 166:6514-6522.
21. Wen R., Cole G.A., Surman S., Blackman M.A., Woodland D.L. Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells. J Exp Med 1996, 183:1083-1092.
22. Wen R., Broussard D.R., Surman S., Hogg T.L., Blackman M.A., Woodland D.L. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells. Eur J Immunol 1997, 27:772-781.
23. Golovkina T.V., Agafonova Y., Kazansky D., Chervonsky A. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens. J Immunol 2001, 166:2244-2250.
24. Azar G.A., Sekaly R.P., Thibodeau J. A defective viral superantigen-presenting phenotype in HLA-DR transfectants is corrected by CIITA. J Immunol 2005, 174:7548-7557.
25. Albert L.J., Denzin L.K., Ghumman B., Bangia N., Cresswell P., Watts T.H. Quantitative defect in staphylococcal enterotoxin A binding and presentation by HLA-DM-deficient T2.Ak cells corrected by transfection of HLA-DM genes. Cell Immunol 1998, 183:42-51.
26. Perraudeau M., Taylor P.R., Stauss H.J., Lindstedt R., Bygrave A.E., Pappin D.J., et al. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur J Immunol 2000, 30:2871-2880.
27. Van Ham M., Van Lith M., Lillemeier B., Tjin E., Grüneberg U., Rahman D., et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J Exp Med 2000, 191:1127-1136.
28. Alfonso C., Williams G.S., Karlsson L. H2-O influence on antigen presentation in H2-E-expressing mice. Eur J Immunol 2003, 33:2014-2021.
29. Alfonso C., Karlsson L. Nonclassical MHC class II molecules. Ann Rev Immunol 2000, 18:113-142.
30. Hornell T.M.C., Burster T., Jahnsen F.L., Pashine A., Ochoa M.T., Harding J.J., et al. Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol 2006, 176:3536-3547.
31. Chen X., Reed-Loisel L.M., Karlsson L., Jensen P.E. H2-O expression in primary dendritic cells. J Immunol 2006, 176:3548-3556.
32. Kropshofer H., Hammerling G.J., Vogt A.B. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules. Immunol Rev 1999, 172:267-278.
33. Karlsson L., Surh C.D., Sprent J., Peterson P.A. A novel class II MHC molecule with unusual tissue distribution. Nature 1991, 351:485-488.
34. Liljedahl M., Kuwana T., Fung-Leung W.P., Jackson M.R., Peterson P.A., Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996, 15:4817-4824.
35. Van Lith M., Van Ham M., Griekspoor A., Tjin E., Verwoerd D., Calafat J., et al. Regulation of MHC class II antigen presentation by sorting of recycling HLA-DM/DO and class II within the multivesicular body. J Immunol 2001, 167:884-892.
36. Chen X., Laur O., Kambayashi T., Li S., Bray R.A., Weber D.A., et al. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J Exp Med 2002, 195:1053-1062.
37. Denzin L.K., Sant'Angelo D.B., Hammond C., Surman M.J., Cresswell P. Negative regulation by HLA-DO of MHC Class II-restricted antigen processing. Science 1997, 278:106-109.
38. Van Ham S.M., Tjin E.P.M., Lillemeier B.F., Gruneberg U., Van Meijgaarden K.E., Pastoors L., et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr Biol 1997, 7:950-957.
39. Liljedahl M., Winqvist O., Surh C.D., Wong P., Ngo K., Teyton L., et al. Altered antigen presentation in mice lacking H2-O. Immunity 1998, 8:233-243.
40. Kropshofer H., Vogt A.B., Thery C., Armandola E.A., Li B.C., Moldenhauer G., et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998, 17:2971-2981.
41. Yi W., Seth N.P., Martillotti T., Wucherpfennig K.W., Sant'Angelo D.B., Denzin L.K. Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J Clin Invest 2010, 120:1324-1336.
42. Qi L., Ostrand-Rosenberg S. H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens. J Immunol 2001, 167:1371-1378.
43. Fu X.-T.T., Karr R.W. HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Hum Immunol 1994, 39:253-260.
44. Wraight C.J., Van Endert P., Moller P., Lipp J., Ling N.R., MacLennan I.C., et al. Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem 1990, 265:5787-5792.
45. Roche P.A., Marks M.S., Cresswell P. Identification of the HLA class II-invariant chain complex as a nine subunit transmembrane glycoprotein. Nature 1991, 354:392-394.
46. Denzin L.K., Robbins N.F., Carboy-Newcomb C., Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1994, 1:595-606.
47. Hammond C., Denzin L.K., Pan M., Griffith J.M., Geuze H.J., Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol 1998, 161:3282-3291.
48. Glazier K.S., Hake S.B., Tobin H.M., Chadburn A., Schattner E.J., Denzin L.K. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J Exp Med 2002, 195:1063-1069.
49. Khalil H., Deshaies F., Bellemare-Pelletier A., Brunet A., Faubert A., Azar G.A., et al. Class II transactivator-induced expression of HLA-DOb in HeLa cells. Tissue Antigens 2002, 60:372-382.
50. Finzi A., Brunet A., Xiao Y., Thibodeau J., Cohen E.A. Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments. J Virol 2006, 80:9789-9797.
51. Robadey C., Ammerlaan W., Muller C., Cloutier I., Sekaly R.P., Haefliger J.A., et al. The processing routes determined by negatively charged residues in DR1-restricted T cell determinants. J Immunol 1997, 159:3238-3246.
52. DeMars R., Chang C.C., Shaw S., Reitnauer P.J., Sondel P.M. Homozygous deletions that simultaneously eliminate expression of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expressio. Hum Immunol 1984, 11:77-97.
53. Brunet A., Samaan A., Deshaies F., Kindt T.J., Thibodeau J. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta. J Biol Chem 2000, 275:37062-37071.
54. Khalil H., Brunet A., Saba I., Terra R., Sekaly R.P., Thibodeau J. The MHC class II beta chain cytoplasmic tail overcomes the invariant chain p35-encoded endoplasmic reticulum retention signal. Int Immunol 2003, 15:1249-1263.
55. Ceman S., Petersen J.W., Pinet V., DeMars R. Gene required for normal MHC class II expression and function is localized to approximately 45kb of DNA in the class II region of the MHC. J Immunol 1994, 152:2865-2873.
56. Dessen A., Lawrence C.M., Cupo S., Zaller D.M., Wiley D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997, 7:473-481.
57. Herman A., Labrecque N., Thibodeau J., Marrack P., Kappler J.W., Sekaly R.P. Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR. Proc Natl Acad Sci USA 1991, 88:9954-9958.
58. Denzin L.K., Fallas J.L., Prendes M., Yi W. Right place, right time, right peptide: DO keeps DM focused. Immunol Rev 2005, 207:279-292.
59. Nagarajan U.M., Bushey A., Boss J.M. Modulation of gene expression by the MHC class II transactivator. J Immunol 2002, 169:5078-5088.
60. Hake S.B., Tobin H.M., Steimle V., Denzin L.K. Comparison of the transcriptional regulation of classical and non-classical MHC class II genes. Eur J Immunol 2003, 33:2361-2371.
61. Fallas J.L., Yi W., Draghi N.A., O'Rourke H.M., Denzin L.K. Expression patterns of H2-O in mouse B cells and dendritic cells correlate with cell function. J Immunol 2007, 178:1488-1497.
62. Karp D.R., Long E.O. Identification of HLA-DR1 b chain residues critical for binding staphylococcal enterotoxins A and E. J Exp Med 1992, 175:415-424.
63. Herman A., Croteau G., Sekaly R.-P., Kappler J., Marrack P. HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J Exp Med 1990, 172:709-717.
64. Petersson K., Hakansson M., Nilsson H., Forsberg G., Svensson L.A., Liljas A., et al. Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence. EMBO J 2001, 20:3306-3312.
65. Li Y., Li H., Dimasi N., McCormick J.K., Martin R., Schuck P., et al. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 2001, 14:93-104.
66. Brocke P., Armandola E., Garbi N., Hammerling G.J., Hämmerling G.J. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes. Eur J Immunol 2003, 33:411-421.
67. Lavoie P.M., Thibodeau J., Cloutier I., Busch R., Sekaly R.P. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM. Proc Natl Acad Sci USA 1997, 94:6892-6897.
68. Porter K.A., Kelley L.N., George A., Harton J.A., Duus K.M. Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag. PLoS One 2010, 5:e11304.
69. Yee C.S.K., Yao Y., Li P., Klemsz M.J., Blum J.S., Chang C.-H., et al. Cathepsin E: a novel target for regulation by class II transactivator. J Immunol 2004, 172:5528-5534.
70. Fallang L.-E., Roh S., Holm A., Bergseng E., Yoon T., Fleckenstein B., et al. Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM. J Immunol 2008, 181:5451-5461.
71. Strubin M., Berte C., Mach B. Alternative splicing and alternative initiation of translation explain the four forms of the Ia antigen-associated invariant chain. EMBO J 1986, 5:3485-3488.
72. Verreck F.A., Fargeas C.A., Hämmerling G.J., Hammerling G.J. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM. Eur J Immunol 2001, 31:1029-1036.
73. Lovitch S.B., Unanue E.R. Conformational isomers of a peptide-class II major histocompatibility complex. Immunol Rev 2005, 207:293-313.
74. Lapointe R., Bellemare-Pelletier A., Housseau F., Thibodeau J., Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003, 63:2836-2843.
75. Bellemare-Pelletier A., Tremblay J., Beaulieu S., Boulassel M.R., Routy J.P., Massie B., et al. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing. J Leukoc Biol 2005, 78:95-105.
76. Roucard C., Thomas C., Pasquier M.A., Trowsdale J., Sotto J.J., Neefjes J., et al. In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation. J Immunol 2001, 167:6849-6858.
77. Newell M.K., Tobin R.P., Cabrera J.H., Sorensen M.B., Huckstep A., Villalobos-Menuey E.M., et al. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leukoc Biol 2010, 88:779-789.
78. Jones D.D., Deiulio G.A., Winslow G.M. Antigen-driven induction of polyreactive IgM during intracellular bacterial infection. J Immunol 2012, 189:1440-1447.
79. Rohn T.A., Boes M., Wolters D., Spindeldreher S., Muller B., Langen H., et al. Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization. Nat Immunol 2004, 5:909-918.
80. Chaturvedi P., Hengeveld R., Zechel M.A., Lee-Chan E., Singh B. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses. Int Immunol 2000, 12:757-765.